Coloplast A/S - CLPBY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$13.26
▲ +0.31 (2.39%)

This chart shows the closing price for CLPBY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Coloplast A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLPBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLPBY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Coloplast A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.26.

This chart shows the closing price for CLPBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Coloplast A/S. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/7/2023Royal Bank of CanadaInitiated CoverageSector Perform
9/5/2023The Goldman Sachs GroupInitiated CoverageNeutral
7/10/2023DNB MarketsUpgradeHold ➝ Buy
6/1/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
5/12/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
3/29/2023BarclaysUpgradeUnderweight ➝ Equal Weight
3/7/2023Sanford C. BernsteinInitiated CoverageMarket Perform
1/10/2023BarclaysLower TargetUnderweight ➝ Underweight835.00 ➝ 815.00
11/22/2022BarclaysBoost TargetUnderweight ➝ Underweight780.00 ➝ 835.00
11/9/2022Credit Suisse GroupLower Target1,100.00 ➝ 1,045.00
11/8/2022UBS GroupLower Target878.00 ➝ 840.00
10/18/2022Morgan StanleyInitiated CoverageOverweight
9/20/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
9/1/2022Credit Suisse GroupBoost TargetOutperform ➝ Outperform1,080.00 ➝ 1,100.00
5/10/2022JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral1,014.00 ➝ 980.00
1/26/2022DNB MarketsUpgradeSell ➝ Hold
1/19/2022JPMorgan Chase & Co.Lower Target1,038.00 ➝ 1,033.00
1/10/2022BarclaysBoost Target975.00 ➝ 990.00
11/11/2021CheuvreuxUpgradeHold ➝ Buy
11/2/2021JPMorgan Chase & Co.Reiterated RatingNeutral
11/2/2021Nordea Equity ResearchDowngradeHold ➝ Sell
10/13/2021BarclaysReiterated RatingEqual Weight
9/10/2021BarclaysReiterated RatingEqual Weight
8/19/2021Credit Suisse GroupReiterated RatingOutperform
8/19/2021JPMorgan Chase & Co.Reiterated RatingNeutral
8/11/2021Kepler Capital MarketsDowngradeBuy ➝ Hold1,144.00
7/15/2021BarclaysReiterated RatingEqual Weight
5/18/2021Berenberg BankReiterated RatingHold
5/7/2021JPMorgan Chase & Co.Reiterated RatingNeutral
3/9/2021CommerzbankUpgradeReduce ➝ Buy
3/8/2021BarclaysUpgradeUnderweight ➝ Equal Weight
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutral
2/3/2021Morgan StanleyReiterated RatingEqual Weight
1/20/2021Berenberg BankUpgradeSell ➝ Hold
1/13/2021BarclaysReiterated RatingUnderweight
12/9/2020Morgan StanleyReiterated RatingEqual Weight
11/6/2020Morgan StanleyReiterated RatingEqual Weight
11/4/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/16/2020Berenberg BankReiterated RatingSell
9/23/2020BarclaysDowngradeEqual Weight ➝ Underweight
9/23/2020Jefferies Financial GroupUpgradeHold ➝ Buy
8/19/2020JPMorgan Chase & Co.Reiterated RatingNeutral
8/19/2020Morgan StanleyReiterated RatingEqual Weight
8/11/2020Nordea Equity ResearchDowngradeHold ➝ Sell
4/27/2020BarclaysReiterated RatingEqual Weight
4/20/2020JPMorgan Chase & Co.Reiterated RatingNeutral
3/18/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral
7/19/2019BarclaysDowngradeOverweight ➝ Equal Weight
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Coloplast A/S logo
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
Read More

Today's Range

Now: $13.26
Low: $13.07
High: $13.26

50 Day Range

MA: $13.40
Low: $12.73
High: $14.30

52 Week Range

Now: $13.26
Low: $9.90
High: $14.77

Volume

67,657 shs

Average Volume

103,320 shs

Market Capitalization

N/A

P/E Ratio

40.18

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Coloplast A/S?

The following Wall Street sell-side analysts have issued stock ratings on Coloplast A/S in the last twelve months: DNB Markets, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for CLPBY.

What is the current price target for Coloplast A/S?

0 Wall Street analysts have set twelve-month price targets for Coloplast A/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Coloplast A/S in the next year.
View the latest price targets for CLPBY.

What is the current consensus analyst rating for Coloplast A/S?

Coloplast A/S currently has 1 sell rating, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CLPBY, but not buy more shares or sell existing shares.
View the latest ratings for CLPBY.

What other companies compete with Coloplast A/S?

How do I contact Coloplast A/S's investor relations team?

Coloplast A/S's physical mailing address is HOLTEDAM 1-3, HUMLEBAEK G7, 3050. The company's listed phone number is (454) 911-1111 and its investor relations email address is [email protected]. The official website for Coloplast A/S is www.coloplast.com. Learn More about contacing Coloplast A/S investor relations.